International Journal of Clinical Research

Objective To observe the clinical effect of alfentanil combined with propofol in painless gastrointestinal endoscopy and provide basis for safer and more reasonable application. Methods 200 patients who underwent painless gastrointestinal endoscopy from March 2022 to February 2024 were selected and randomly divided into the propofol combined with alfentanil group (PA group) and the propofol combined with sufentanil group. (PS group), 100 people in each group. Postoperative recovery time, vital signs, propofol dosage, sedation score and adverse events were recorded to evaluate satisfaction. Results The recovery and recovery room stay time of the PA group was significantly shorter than that of the PS group (P＜0.05); the heart rate of the PA group was higher than that of the PS group at 1 and 3 minutes after induction (P＜0.05). The induction time, incidence of hypotension and dopamine dosage in the PS group were higher than those in the PA group (P＜0.05); blood oxygen saturation was different at certain time points but was all above 95%. The patient and anesthesiologist satisfaction in the PA group was significantly higher than that in the PS group (P＜0.05). Conclusion Compared with sufentanil, alfentanil combined with propofol has faster recovery, more stable circulatory system and fewer adverse reactions in painless gastrointestinal endoscopy, which improves satisfaction.

Afentanil; Sufentanil; Gastroenteroscopy